Indolent Lymphoma
Showing 1 - 25 of 5,238
Indolent Lymphoma, Low-dose Radiotherapy Trial in Beijing (Low-dose radiotherapy)
Recruiting
- Indolent Lymphoma
- Low-dose Radiotherapy
- Low-dose radiotherapy
-
Beijing, Beijing, ChinaNational Cancer Center/National Clinical Research Center for Can
Sep 13, 2022
Ocular Adnexal Mucosa-Associated Lymphoid Tissue Lymphoma Trial in Milano (intralesional rituximab, supplemental autologous
Completed
- Ocular Adnexal Mucosa-Associated Lymphoid Tissue Lymphoma
- intralesional rituximab
- supplemental autologous serum
-
Milano, ItalyDip. Oncoematologia - Fondazione Centro San Raffaele del Monte T
Aug 2, 2022
Inert Non Hodgkin's Lymphoma Trial in Beijing (IBI376, Rituximab)
Recruiting
- Inert Non Hodgkin's Lymphoma
- IBI376
- Rituximab
-
Beijing, ChinaBiotherapeutic Department, Chinese PLA General Hospital
Feb 19, 2022
Ann Arbor Stage I B-Cell Non-Hodgkin Lymphoma, Ann Arbor Stage I Grade 1 Follicular Lymphoma, Ann Arbor Stage I Grade 2
Active, not recruiting
- Ann Arbor Stage I B-Cell Non-Hodgkin Lymphoma
- +22 more
- External Beam Radiation Therapy
- Orbital Radiation
-
Houston, TexasM D Anderson Cancer Center
Dec 9, 2022
Follicular Lymphoma, Marginal Zone Lymphoma, Mantle Cell Lymphoma Trial run by the NCI (Obinutuzumab, Venetoclax, Magrolimab)
Recruiting
- Follicular Lymphoma
- +4 more
- Obinutuzumab
- +2 more
-
Bethesda, MarylandNational Institutes of Health Clinical Center
Jan 20, 2023
Grade 3a Follicular Lymphoma, Recurrent Follicular Lymphoma, Recurrent Grade 1 Follicular Lymphoma Trial in Houston (other,
Completed
- Grade 3a Follicular Lymphoma
- +9 more
- Laboratory Biomarker Analysis
- +2 more
-
Houston, TexasM D Anderson Cancer Center
Jan 31, 2023
Patterns in People With Indolent Non-Hodgkin Lymphoma,Type of
Active, not recruiting
- Relapsed or Refractory Indolent Non-Hodgkin Lymphoma
- Copanlisib (BAY80-6946)
-
Multiple Locations, TaiwanMany Locations
Jan 31, 2023
Relapsed/Refractory Indolent B Cell Non-Hodgkin Lymphomas Trial in Boston (Imprime PGG, Rituximab)
Completed
- Relapsed/Refractory Indolent B Cell Non-Hodgkin Lymphomas
- Imprime PGG
- Rituximab
-
Boston, MassachusettsDana Farber Cancer Institute
Sep 20, 2022
CD20-positive Non-Hodgkin Lymphoma Trial in Seoul (Rituximab + MG4101)
Terminated
- CD20-positive Non-Hodgkin Lymphoma
- Rituximab + MG4101
-
Seoul, Korea, Republic ofSeoul National University Hospital
Oct 24, 2022
Indolent Lymphoma Trial in Tel Aviv (vegan diet and lifestyle changes)
Recruiting
- Indolent Lymphoma
- vegan diet and lifestyle changes
-
Tel Aviv, IsraelTel-Aviv Sourasky Medical Center
Jul 5, 2021
CLL, SLL, Richter's Transformation Trial in United States (TG-1801, Ublituximab)
Recruiting
- CLL
- +9 more
- TG-1801
- Ublituximab
-
Fayetteville, Arkansas
- +4 more
Jan 20, 2023
Marginal Zone Lymphoma, Follicular Lymphoma, DLBCL Trial in China (Zanubrutinib, Rituximab)
Completed
- Marginal Zone Lymphoma
- +2 more
-
Harbin, Heilongjiang, China
- +3 more
Oct 26, 2021
Lymphoma Trial in Houston (Ibritumomab Tiuxetan (Zevalin), Rituximab)
Completed
- Lymphoma
- Ibritumomab Tiuxetan (Zevalin)
- Rituximab
-
Houston, TexasUniversity of Texas MD Anderson Cancer Center
Aug 30, 2022
Follicular Lymphoma, Small Lymphocytic Lymphoma, Marginal Zone Lymphoma Trial in United States (dietary supplement, biological,
Active, not recruiting
- Follicular Lymphoma
- +3 more
- Vitamin D
- +2 more
-
Miami, Florida
- +6 more
Mar 6, 2022
Severe COVID-19 Infection in CLL or B-NHL Who Received
Not yet recruiting
- Chronic Lymphocytic Leukemia
- +2 more
- (no location specified)
Apr 6, 2023
Recurrent Follicular Lymphoma, Recurrent Marginal Zone Lymphoma, Recurrent Nodal Marginal Zone Lymphoma Trial (Acalabrutinib,
Withdrawn
- Recurrent Follicular Lymphoma
- +8 more
- (no location specified)
Jun 2, 2022
Lymphoma, B-Cell Trial in Guangzhou (Rituximab Biosimilar, Pegylated Interferon a-2b)
Recruiting
- Lymphoma, B-Cell
- Rituximab Biosimilar
- Pegylated Interferon α-2b
-
Guangzhou, Guangdong, ChinaDepartment of Medical Oncology, Sun Yat-sen University Cancer Ce
Apr 6, 2022
Follicular Lymphoma, Marginal Zone Lymphoma, Indolent Non-hodgkin Lymphoma Trial in Boston (Obinutuzumab, Glofitamab)
Not yet recruiting
- Follicular Lymphoma
- +2 more
-
Boston, MassachusettsDana-Farber Cancer Institute
Mar 13, 2023
Waldenstrom Macroglobulinemia Trial in United States (Umbralisib)
Completed
- Waldenstrom Macroglobulinemia
-
Washington, District of Columbia
- +3 more
Oct 19, 2022
Chronic Lymphocytic Leukemia, Mantle Cell Lymphoma, Follicular Lymphoma Trial in Spokane, Salamanca (Zilovertamab vedotin,
Recruiting
- Chronic Lymphocytic Leukemia
- +3 more
- Zilovertamab vedotin
- Nemtabrutinib
-
Spokane, Washington
- +1 more
Aug 12, 2022
Recurrent B-Cell Non-Hodgkin Lymphoma, Recurrent Follicular Lymphoma, Recurrent Indolent Adult Non-Hodgkin Lymphoma Trial in
Suspended
- Recurrent B-Cell Non-Hodgkin Lymphoma
- +7 more
- Venetoclax
- +3 more
-
Philadelphia, PennsylvaniaSidney Kimmel Cancer Center at Thomas Jefferson University
Jan 20, 2023